MedTrace Logo

Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days

NCT01120418 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2012-08-13

No results posted yet for this study

Summary

The objective of this study is to evaluate the effect on corneal endothelial cell density changes when ISV-403 is administered for five (5) days compared to no drug treatment, in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

Besifloxacin Ophthalmic Suspension 0.6%

administered 3 times a day for 5 days to one eye.

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Laura Trusso, MS · Bausch & Lomb Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2007-10-31
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01120418 on ClinicalTrials.gov